Major depressive disorders are as prevalent as they've ever been. It's only getting worse and it's a major burden on society both financially and in relation to quality of life.

This problem isn’t just going away by itself. The aging population is increasing rapidly and depressive disorders are common among this demographic. But even among young and relatively healthy people, countless millennials and Generation Z's are diagnosed or, even worse, undiagnosed but still suffering from depression.

The traditional antidepressant drug market has a bad reputation and for a good reason. Not everyone wants to take the chance of forming a habit. Many people don't want these chemicals in their bodies.

There's a serious problem here, but with every problem comes an opportunity. Champignon Brands (CSE: SHRM, OTC: SHRMF) is seizing this opportunity by pursuing the development and commercialization of alternative treatments for depressive disorders. Champignon has the world's greatest footprint with respect to depression research according to Expertscape, as measured by clinical infrastructure and human capital.

Medical professionals are finally recognizing the potential of psychedelics to treat depressive disorders. Among these solutions is ketamine, which has been fast-tracked by the U.S. Food and Drug Administration for approval in treating major depression. On top of that, the FDA has granted breakthrough therapy status to further the study of psilocybin and ketamine remedies.


The FDA isn't the only one recognizing the potential. Ketamine has been listed by the World Health Organization as an important anesthetic and has been used off-label for depression, anxiety, pain, and post-traumatic stress disorder.

Champignon was ahead of the curve on this regulator-supported breakthrough technology. The company has a fully operational clinic and co-loctaed pharmacy located in Mississauga, Ontario for the purpose of developing and delivering treatments based on ketamine and psilocybin. Champignon also just announced an aquisiton of a California-based Wellness Clinic of Orange County, which owns and operates a state-of-the-art ketamine infusion treatment centre located within Mission Hospital’s Laguna Beach campus.

You won't find any real competition, as Champignon is currently the only Health Canada-approved clinic to conduct randomized controlled trials (RCT) of psilocybin. Talk about having what Warren Buffett calls an economic moat – Champignon is operating as a pioneer in this niche!

With 16 months of operating history, Champignon's Ontario clinic already earned roughly $1,000,000 in revenue in its first full year of operation. Over 1,500 ketamine treatments have been administered, with more than 300 patients serviced at the Ontario clinic.

This pioneering clinic is fully licensed by the College of Physicians and Surgeons Ontario (CPSO) to perform ketamine treatments for a range of conditions, including but not limited to depression, bipolar disorder, PTSD, and OCD.

History was made when the Ontario clinic was licensed by Health Canada to provide eligible patients with psilocybin and it became the only clinic in all of Canada to perform psilocybin doses under Health Canada's approval.

Just for those achievements alone, Champignon Brands could be remembered as the trailblazer in deliverying ketamine solutions for major depressive and related disorders. It's a real threat to the traditional regime of addictive, chemical-filled drugs that have burdened society.

Champignon Brands CAN steal market share from the old traditional medicine regime that's been in power for so many years. This company is doing what others couldn't even imagine, and the market will never be the same.


Consider becoming a shareholder of Champignon Brands (CSE: SHRM, OTC: SHRMF)!

For further updates on Champignon Brands​, subscribe now!

    We are not brokers, investment or financial advisers, and you should not rely on the information herein as investment advice. We are a marketing company. If you are seeking personal investment advice, please contact a qualified and registered broker, investment adviser or financial adviser. You should not make any investment decisions based on our communications. You should know that we have been compensated three hundred thousand dollars, directly by the company, for a two year public awareness campaign. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT recommendations. The securities issued by the companies we profile should be considered high risk and, if you do invest, you may lose your entire investment. Please do your own research before investing, including reading the companies’ SEC filings, press releases, and risk disclosures. Information contained in this profile was provided by the company, extracted from SEC filings, company websites, and other publicly available sources. We believe the sources and information are accurate and reliable but we cannot guarantee it.

    Please read our full disclaimer at